Jennifer Gillis

Jennifer Gillis

Auto-generated profile, based on publicly available information

Jennifer Gillis

Surveillance, Canadian Cancer Society

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Victor C. M. LeungVictor C. M. Leung
Victor C. M. Leung
JGJennifer Gillis
Jennifer Gillis
JRJanet Raboud
Janet Raboud
CCCurtis Cooper
Curtis Cooper
RHRobert S Hogg
Robert S Hogg
CCCANOC Collaboration
CANOC Collaboration
HIV leads to CD4:CD8 ratio inversion as immune dysregulation progresses. We examined the predictors of CD4:CD8 normalization after combination antiretroviral therapy (cART) and determined whether normalization is associated with reduced progression to AIDS-defining illnesses (ADI) and death. A Canadian cohort of HIV-positive adults with CD4:CD830 days apart, and (2) ADI and death from all causes were assessed using adjusted proportional hazards models. 4206 patients were studied for a median of 2.77 years and 306 (7.2%) normalized their CD4:CD8 ratio. Factors associated with achieving a normal CD4:CD8 ratio were: baseline CD4+ T-cells >350 cells/mm3, baseline CD8+ T-cells <500 cells/mm3, time-updated HIV RNA suppression, and not reporting sex with other men as a risk factor. There were 213 ADIs and 214 deaths in 13476 person-years of follow-up. Achieving a normal CD4:CD8 ratio was not associated with time to ADI/death. In our study, few individuals normalized their CD4:CD8 ratios within the first few years of initiating modern cART. This large study showed no additional short-term predictive value of the CD4:CD8 ratio for clinical outcomes after accounting for other risk factors including age and HIV RNA.

1 April 2013 in Antiviral Therapy
Verified
Journal Article
Closed access
JGJennifer Gillis
Jennifer Gillis
MSMarek Smieja
Marek Smieja
ACAngela Cescon
Angela Cescon
SRSean B Rourke
Sean B Rourke
ABAnn N Burchell
Ann N Burchell
CPColleen Price
Colleen Price
Background: The increased risk for cardiovascular disease (CVD) in HIV is well established. Despite high prevalence of viral hepatitis coinfection with HIV, there are few studies on the risk of CVD amongst antiretroviral therapy (ART)-treated coinfected patients. Methods: Ontario HIV Treatment Network Cohort Study participants who initiated ART without prior CVD events were analysed. HBV and HCV coinfection were identified by serology and RNA test results. CVD was defined as any of: coronary artery disease including atherosclerosis, chronic ischaemic heart disease and arteriosclerotic vascular disease; myocardial infarction; congestive heart failure; cerebrovascular accident or stroke; coronary bypass; angioplasty; and sudden cardiac death. The impact of HBV and HCV coinfection on time to CVD was assessed using multivariable competing risk models accounting for left truncation between ART initiation and study enrolment. Results: A total of 3,416 HIV-monoinfected, 432 HIV-HBV- and 736 HIV–HCV-coinfected individuals were followed for a median (IQR) of 2.32 years (1.36–8.02). Over the study period, 167 CVD events and 613 deaths were documented. After adjustment for age, gender, race, year initiating ART, weight and smoking status, HBV was not associated with time to CVD onset (aHR=1.05, 95% CI [0.63, 1.74]; P=0.86). There was an elevated risk of CVD for HCV-coinfected individuals, which approached statistical significance (aHR=1.44, 95% CI [0.97, 2.13]; P=0.07). Conclusions: Our results are consistent with a moderate increase of CVD among individuals with HIV–HCV coinfection relative to those with HIV infection alone, lending support to consideration of initiation of HCV antiviral treatment.

7 August 2020 in Journal of Autism and Developmental Disorders
Verified
Journal Article
Closed access
PDF file
AMAbbey J. McClemont
Abbey J. McClemont
HMHannah E. Morton
Hannah E. Morton
JGJennifer M. Gillis
Jennifer M. Gillis
RRRaymond G. Romanczyk
Raymond G. Romanczyk

1 June 2020 in The Permanente Journal
Verified
Journal Article
Closed access
KWKathryn Wiens
Kathryn Wiens
JGJennifer Gillis
Jennifer Gillis
INIoana Nicolau
Ioana Nicolau
TWTerrance J Wade
Terrance J Wade
Kathryn Wiens, MSc1; Jennifer Gillis, MSc1; Ioana Nicolau, MSc1; Terrance...

21 February 2020 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
JGJennifer L. Gillis
Jennifer L. Gillis
TGTroy Grennan
Troy Grennan
RGRamandip Grewal
Ramandip Grewal
GOGina Ogilvie
Gina Ogilvie
MGMark Gaspar
Mark Gaspar
TTthe OHTN Cohort Study Team
the OHTN Cohort Study Team
Background: Our objective was to quantify the extent of anal cancer screening among men receiving HIV specialty care in Ontario, Canada, and evaluate factors associated with screening. Setting: Cross-sectional questionnaire within a multisite clinical HIV cohort. Methods: A questionnaire assessing knowledge and experience with human papillomavirus–associated diseases and their prevention was administered in 2016–2017 to 1677 men in the Ontario HIV Treatment Network Cohort Study. We used logistic regression to identify factors associated with having discussed screening with a health care provider and self-reported receipt of screening [digital anal rectal examinations (DARE); anal cytology or anoscopy]. Results reported as adjusted odds ratios (aORs) with 95% confidence intervals (CIs). Results: Forty percent of men reported ever having had anal cytology/anoscopy, and 70% had ever had DARE. After accounting for differences in age, sexual orientation, years since HIV diagnosis, previous diagnosis with AIDS, knowing someone with human papillomavirus–associated cancer, comfort discussing anal health, education, and income, the proportion screened differed by self-identified race. Compared with white men, Asian men were less likely to have discussed screening with a health care provider (aOR = 0.48; 95% CI: 0.29 to 0.80) or to have been screened by DARE (aOR = 0.27; 95% CI: 0.17 to 0.44) or anal cytology/anoscopy (aOR = 0.51; 95% CI: 0.31 to 0.83), and African, Caribbean, or black men (aOR = 0.47; 95% CI: 0.31 to 0.70) were less likely to have had DARE. Results were consistent when restricting the analyses to gay, bisexual, and other men who have sex with men. Conclusion: Our findings highlight the potential for disparities in anal cancer screening that need to be considered when developing guidelines and screening programs to reduce the burden of anal cancer among men living with HIV and ensure health equity.

1 January 2011 in Research in Autism Spectrum Disorders
Verified
Journal Article
Closed access
JGJennifer M. Gillis
Jennifer M. Gillis
ECEmily H. Callahan
Emily H. Callahan
RRRaymond G. Romanczyk
Raymond G. Romanczyk